Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Roche Venture Fund
AddedFeb 13, 2024
UpdatedJul 16, 2026
Roche Venture Fund

Roche Venture Fund

Operating

Swiss-based Roche Venture Fund invests in innovative life science companies globally, managing a diverse portfolio with CHF 500 million.

Location
Basel, Basel-Stadt, CH
Founded
2002
Firm
Compare
Portfolio
Employees

Investments

Cour Pharmaceuticals Development
Cour Pharmaceuticals Development

Total Raised

$135.5M

Rounds

4

Series A$105MJanuary 2024
Aligos Therapeutics
Aligos Therapeutics
Public

Total Raised

$400.6M

Rounds

5

Post Ipo Equity$92MOctober 2023
Series B$125MJanuary 2020
Series A$100MJanuary 2018
Bonum Therapeutics
Bonum Therapeutics

Total Raised

$93M

Rounds

1

Series A$93MNovember 2022
Freenome
Freenome

Total Raised

$1.1B

Rounds

8

Series D$300MDecember 2021
Series C$270MAugust 2020
Series B$160MJuly 2019
Soteria Biotherapeutics
Soteria Biotherapeutics

Total Raised

$42M

Rounds

1

Series A$42MMay 2021
Arch Oncology
Arch Oncology

Total Raised

$250.4M

Rounds

5

Series C$105MApril 2021
Series B$50MMarch 2019
Series A$86MAugust 2016
Entrada Therapeutics
Entrada Therapeutics
Public

Total Raised

$201.6M

Rounds

5

Series B$116MMarch 2021
Series A$59MDecember 2018
Palladio Biosciences
Palladio Biosciences

Total Raised

$20M

Rounds

2

Series B$20MSeptember 2020
Black Diamond Therapeutics
Black Diamond Therapeutics
Public

Total Raised

$272.1M

Rounds

6

Series C$85MDecember 2019
Series B$85MJanuary 2019
BlueLight Therapeutics
BlueLight Therapeutics

Total Raised

$46.6M

Rounds

6

Series C$20MSeptember 2018
Series B$10MJanuary 2016
CiVi Biopharma
CiVi Biopharma
Public

Total Raised

$89M

Rounds

2

Series Unknown$49MMay 2018
Ideaya Biosciences
Ideaya Biosciences
Public

Total Raised

$431.1M

Rounds

7

Series B$94MMarch 2018
Syapse
Syapse
Public

Total Raised

$222.6M

Rounds

9

Series D$30MNovember 2017
Second Genome
Second Genome
Acquired

Total Raised

$62.5M

Rounds

4

Series B$51MApril 2016
Lumos Pharma
Lumos Pharma
Public

Total Raised

$53.5M

Rounds

4

Series B$34MApril 2016
Lysosomal Therapeutics
Lysosomal Therapeutics

Total Raised

$24.8M

Rounds

2

Series A$20MFebruary 2015